Literature DB >> 20008948

Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Michael J Ostacher1, Roy H Perlis, Andrew A Nierenberg, Joseph Calabrese, Jonathan P Stange, Ihsan Salloum, Roger D Weiss, Gary S Sachs.   

Abstract

OBJECTIVE: Bipolar disorder is highly comorbid with substance use disorders, and this comorbidity may be associated with a more severe course of illness, but the impact of comorbid substance abuse on recovery from major depressive episodes in these patients has not been adequately examined. The authors hypothesized that comorbid drug and alcohol use disorders would be associated with longer time to recovery in patients with bipolar disorder.
METHOD: Subjects (N=3,750) with bipolar I or bipolar II disorder enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) were followed prospectively for up to 2 years. Prospectively observed depressive episodes were identified for this analysis. Subjects with a past or current drug or alcohol use disorder were compared with those with no history of drug or alcohol use disorders on time to recovery from depression and time until switch to a manic, hypomanic, or mixed episode.
RESULTS: During follow up, 2,154 subjects developed a new-onset major depressive episode; of these, 457 subjects switched to a manic, hypomanic, or mixed episode prior to recovery. Past or current substance use disorder did not predict time to recovery from a depressive episode relative to no substance use comorbidity. However, those with current or past substance use disorder were more likely to experience switch from depression directly to a manic, hypomanic, or mixed state.
CONCLUSIONS: Current or past substance use disorders were not associated with longer time to recovery from depression but may contribute to greater risk of switch into manic, mixed, or hypomanic states. The mechanism conferring this increased risk merits further study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008948      PMCID: PMC2918249          DOI: 10.1176/appi.ajp.2009.09020299

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  23 in total

1.  Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders.

Authors:  M W Otto; N M Simon; S R Wisniewski; D J Miklowitz; J N Kogan; N A Reilly-Harrington; E Frank; A A Nierenberg; L B Marangell; K Sagduyu; R D Weiss; S Miyahara; M E Thas; G S Sachs; M H Pollack
Journal:  Br J Psychiatry       Date:  2006-07       Impact factor: 9.319

2.  Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years.

Authors:  Lauren B Marangell; Mark S Bauer; Ellen B Dennehy; Stephen R Wisniewski; Michael H Allen; David J Miklowitz; Maria A Oquendo; Ellen Frank; Roy H Perlis; James M Martinez; Andrea Fagiolini; Michael W Otto; Cheryl A Chessick; Holly A Zboyan; Sachiko Miyahara; Gary Sachs; Michael E Thase
Journal:  Bipolar Disord       Date:  2006-10       Impact factor: 6.744

3.  Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania.

Authors:  Stephen M Strakowski; Melissa P DelBello; David E Fleck; Caleb M Adler; Robert M Anthenelli; Paul E Keck; Lesley M Arnold; Jennifer Amicone
Journal:  Arch Gen Psychiatry       Date:  2007-01

4.  The association between moderate alcohol use and illness severity in bipolar disorder: a preliminary report.

Authors:  Benjamin I Goldstein; Vytas P Velyvis; Sagar V Parikh
Journal:  J Clin Psychiatry       Date:  2006-01       Impact factor: 4.384

5.  Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: data from the first 1000 STEP-BD participants.

Authors:  Mark D Fossey; Michael W Otto; William R Yates; Steve R Wisniewski; Laszlo Gyulai; Michael H Allen; David J Miklowitz; Kim A Coon; Michael J Ostacher; Jackie L Neel; Michael E Thase; Gary S Sachs; Roger D Weiss
Journal:  Am J Addict       Date:  2006 Mar-Apr

6.  Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic.

Authors:  Martha Sajatovic; Rosalinda V Ignacio; Jane A West; Kristin A Cassidy; Roknedin Safavi; Amy M Kilbourne; Frederic C Blow
Journal:  Compr Psychiatry       Date:  2008-08-23       Impact factor: 3.735

7.  Concordance with treatment guidelines for bipolar disorder: data from the systematic treatment enhancement program for bipolar disorder.

Authors:  Ellen B Dennehy; Mark S Bauer; Roy H Perlis; Jane N Kogan; Gary S Sachs
Journal:  Psychopharmacol Bull       Date:  2007

8.  Medical and substance use comorbidity in bipolar disorder.

Authors:  David E Kemp; Keming Gao; Stephen J Ganocy; Emily Caldes; Kathryn Feldman; Philip K Chan; Carla Conroy; Sarah Bilali; Robert L Findling; Joseph R Calabrese
Journal:  J Affect Disord       Date:  2008-12-18       Impact factor: 4.839

9.  Factors associated with treatment nonadherence among US bipolar disorder patients.

Authors:  Ross J Baldessarini; Richard Perry; James Pike
Journal:  Hum Psychopharmacol       Date:  2008-03       Impact factor: 1.672

10.  Depression precipitated by alcohol use in patients with co-occurring bipolar and substance use disorders.

Authors:  William B Jaffee; Margaret L Griffin; Robert Gallop; Christina S Meade; Fiona Graff; Rachel E Bender; Roger D Weiss
Journal:  J Clin Psychiatry       Date:  2008-12-30       Impact factor: 4.384

View more
  27 in total

1.  Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate.

Authors:  James J Prisciandaro; Stacia M DeSantis; Cody Chiuzan; Delisa G Brown; Kathleen T Brady; Bryan K Tolliver
Journal:  Alcohol Clin Exp Res       Date:  2011-09-20       Impact factor: 3.455

2.  The role of lifetime anxiety history in the course of bipolar spectrum disorders.

Authors:  Madison K Titone; Rachel D Freed; Jared K O'Garro-Moore; Andrew Gepty; Tommy H Ng; Jonathan P Stange; Lyn Y Abramson; Lauren B Alloy
Journal:  Psychiatry Res       Date:  2018-04-03       Impact factor: 3.222

3.  Risk and protective factors associated with substance use disorders in adolescents with first-episode mania.

Authors:  Jacob R Stephens; Jaimee L Heffner; Caleb M Adler; Thomas J Blom; Robert M Anthenelli; David E Fleck; Jeffrey A Welge; Stephen M Strakowski; Melissa P DelBello
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-05-10       Impact factor: 8.829

4.  The influence of comorbid disorders on the episodicity of bipolar disorder in youth.

Authors:  S Yen; R Stout; H Hower; M A Killam; L M Weinstock; D R Topor; D P Dickstein; J I Hunt; M K Gill; T R Goldstein; B I Goldstein; N D Ryan; M Strober; R Sala; D A Axelson; B Birmaher; M B Keller
Journal:  Acta Psychiatr Scand       Date:  2015-10-17       Impact factor: 6.392

5.  A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use.

Authors:  Keming Gao; Stephen J Ganocy; Carla Conroy; Brittany Brownrigg; Mary Beth Serrano; Joseph R Calabrese
Journal:  Psychopharmacology (Berl)       Date:  2017-05-24       Impact factor: 4.530

6.  Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.

Authors:  David A Luckenbaugh; Lobna Ibrahim; Nancy Brutsche; Jose Franco-Chaves; Daniel Mathews; Craig A Marquardt; Christy Cassarly; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2012-09-14       Impact factor: 6.744

7.  Identification and initial validation of empirically derived bipolar symptom states from a large longitudinal dataset: an application of hidden Markov modeling to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study.

Authors:  James J Prisciandaro; Bryan K Tolliver; Stacia M DeSantis
Journal:  Psychol Med       Date:  2018-08-29       Impact factor: 7.723

Review 8.  Current status of co-occurring mood and substance use disorders: a new therapeutic target.

Authors:  Helen M Pettinati; Charles P O'Brien; William D Dundon
Journal:  Am J Psychiatry       Date:  2013-01       Impact factor: 18.112

9.  The impact of substance use disorders on recovery from bipolar depression: Results from the Systematic Treatment Enhancement Program for Bipolar Disorder psychosocial treatment trial.

Authors:  Alexandra K Gold; Amy T Peters; Michael W Otto; Louisa G Sylvia; Pedro Vieira da Silva Magalhaes; Michael Berk; Darin D Dougherty; David J Miklowitz; Ellen Frank; Andrew A Nierenberg; Thilo Deckersbach
Journal:  Aust N Z J Psychiatry       Date:  2018-07-26       Impact factor: 5.744

10.  Functional TSPO polymorphism predicts variance in the diurnal cortisol rhythm in bipolar disorder.

Authors:  Alan R Prossin; Matthew Chandler; Kelly A Ryan; Erika F Saunders; Masoud Kamali; Vassilios Papadopoulos; Sebastian Zöllner; Robert Dantzer; Melvin G McInnis
Journal:  Psychoneuroendocrinology       Date:  2018-01-31       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.